Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

682
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
682
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

275
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
275
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Skin Cancer01:30

Skin Cancer

4.7K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraosseous Venous Malformation of the Rib With EWSR1-NFATC1 Fusion Mimicking Malignancy: A Pediatric Case Report.

Journal of pediatric hematology/oncology·2026
Same author

<i>Letter:</i> Biological Therapies for Prurigo Nodularis in Systemic Disease.

Dermatitis : contact, atopic, occupational, drug·2025
Same author

Breaking the Itch-Scratch Cycle: An Integrative Approach for Atopic Dermatitis.

Dermatitis : contact, atopic, occupational, drug·2025
Same author

Cutaneous Juvenile Xanthogranuloma With MRC1::PDGFRB Gene Fusion: A Case Report.

Pediatric dermatology·2025
Same author

A multidisciplinary Delphi consensus on the modern definition of pruritus: Sensation and disease.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Related Experiment Video

Updated: Sep 24, 2025

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

3.4K

Immunotargets and Therapy for Prurigo Nodularis.

Angelina Labib1, Teresa Ju1, Ashley Vander Does1

  • 1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Immunotargets and Therapy
|May 3, 2022
PubMed
Summary

Prurigo nodularis is a chronic skin disease causing intensely itchy nodules. This review covers current immunomodulating treatments and novel immunotherapies for managing this debilitating condition.

Keywords:
IL-31 inhibitorsIL-4 antagonistsJAK inhibitorimmunotherapyoncostatin inhibitorpathogenesisprurigo nodularistreatment

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

568
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K

Related Experiment Videos

Last Updated: Sep 24, 2025

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

3.4K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

568
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.0K

Area of Science:

  • Immunology
  • Dermatology
  • Neuroscience

Background:

  • Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severely pruritic nodules.
  • The condition results from immunological dysregulation and neural amplification involving T-lymphocytes, mast cells, and cytokines.
  • There is a lack of approved treatments and consensus on management, with current therapies being off-label.

Purpose of the Study:

  • To review current immunomodulating treatments for prurigo nodularis.
  • To highlight key targets within the immune cascade involved in PN.
  • To explore emerging immunotherapies on the horizon for PN management.

Main Methods:

  • Literature review of immunological and therapeutic aspects of prurigo nodularis.
  • Analysis of key immune cells and cytokines implicated in PN pathogenesis.
  • Examination of existing and investigational treatment strategies.

Main Results:

  • Immunomodulators form the basis of current PN treatment.
  • Several novel therapies targeting specific immune pathways are under investigation.
  • Understanding the immunological basis is crucial for developing effective treatments.

Conclusions:

  • Effective management of prurigo nodularis requires addressing underlying immunological dysregulation.
  • Current treatment relies on immunomodulators, with promising immunotherapies in development.
  • Further research into targeted therapies is essential for improving patient outcomes in PN.